NEW YORK CITY -- Schizophrenia patients who had recently been released from jail were less likely to be re-arrested or otherwise fail treatment when they took a depot antipsychotic drug compared with ...

The US FDA has granted priority review status to Johnson & Johnson’s paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times a ...